Product Description
GW 590735 is a selective and potent agonist of peroxisome proliferator-activated receptor alpha (PPAR_), a ligand-activated transcription factor that plays a key role in lipid homeostasis. Activation of PPAR_ results in increased clearance of triglyceride (TG) rich very low-density lipoprotein. GW 590735 was in phase II clinical trial for the treatment of dyslipidemia, but that study was discontinued. (Sourced from: https://drugs.ncats.io/drug/QKY617BBX5)
Mechanisms of Action: PPAR-a Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dyslipidemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00388180 |
PAD100958 | N/A |
Completed |
Obesity|Dyslipidemia|Hypercholesterolemia|Inflammation |
None |
2019-03-21 |
Treatments |
|
NCT00169559 |
PAA20001 | P2 |
Completed |
Dyslipidemia |
2005-04-01 |
2019-03-21 |
Treatments |